Obviously this implies a disruption of current drug discovery approaches as well as related business models, which constitutes a major challenge to the pharmaceutical industry and therewith to all, executives and scientific leaders as well.

FORBES: Does Pharma's Innovation Difficulties Reflect Bad Leaders or Tough Circumstances?

O. 12866, then the Statement of Energy Effects should be prepared at the level of detail and analytic effort commensurate with the RIA. If the significant energy action has less economic impact, then the level of detail and analytic effort should be commensurate therewith.

WHITEHOUSE: Memoranda 01-27 (Guidance for Implementing E.O. 13211)